Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

Market Analysis and Insights: Global Antisense & RNAi Therapeutics Market
The global Antisense & RNAi Therapeutics market size is projected to reach US$ 1287.2 million by 2027, from US$ 958.5 million in 2020, at a CAGR of 4.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense & RNAi Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense & RNAi Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense & RNAi Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense & RNAi Therapeutics market.

Global Antisense & RNAi Therapeutics Scope and Market Size
Antisense & RNAi Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antisense & RNAi Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
RNA Interference
SiRNA
MiRNA
Antisense RNA

Segment by Application
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.